Analysts are intrested in these 5 stocks: ( ($AFRM) ), ( ($GRAB) ), ( ($VKTX) ), ( ($PFE) ) and ( ($LLY) ). Here is a ...

What Happened? A number of stocks fell in the afternoon session after stocks gave back some of the gains from the previous ...

Pharmaceutical stocks, including Pfizer (PFE), Novo Nordisk (NVO), and Eli Lilly (LLY), are under pressure after President Trump announced that there may be pharmaceutical tariffs underway.

Shares in many large drugmakers initially fell Wednesday on the president's threat, only to rebound later when he announced a ...

Eli Lilly, which had seen a three-day decline ... The price target was cut to $194 from $212. Pfizer also moved down to Neutral, with its target reduced to $25 from $32. Goldman thinks the ...

The exemption may be short-lived if President Trump makes good on threats to use tariffs as leverage to bring drug production ...

Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...

Sangamo Therapeutics has stacked up $18 million cash from Eli Lilly in a licensing deal that will let the pharma use the ...

In a report released today, Akash Tewari from Jefferies maintained a Buy rating on Pfizer (PFE – Research Report), with a price target of ...

The company has a looming opportunity to grab the booming GLP-1 agonist market by the horns.

Shares of drug companies including AbbVie, Eli Lilly, Pfizer and Merck were recently up 1% to 2% immediately following Trump's announcement, reversing 3% to 5% drops earlier in the day. The Dow Jones ...

If Eli Lilly's oral GLP-1 agonist spends meaningful time on the market as the only approved oral drug, it could significantly shift market share. Pfizer is also working on an oral GLP-1 agonist ...